Understanding a therapy’s mechanism of action is critical for advancing oncology candidates from discovery to the clinic. But deciphering drug impact on signaling pathways, gene expression, and tumor metabolism requires more than just efficacy endpoints – it calls for physiologically relevant in vivo models.

INOVOTION’s CAM (Chorioallantoic Membrane) model has been validated for in-depth mechanistic studies, including transcriptomic profiling, metabolic phenotyping, and MoA evaluation, offering rapid, scalable insights with clinical relevance.

Here’s how recent research supports the CAM model for MoA studies:

1. Transcriptomics: Osimertinib Action in EGFR-mutant NSCLC
“Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon-19-deleted advanced NSCLC mutation”
Barthélémy D et al. (2025). FEBS Open Bio
Using EGFR exon 19–mutated NSCLC xenografts, this study combined Inovotion’s CAM model with transcriptomic analysis, revealing osimertinib’s effect on EGFR signaling, chemotaxis, angiogenesis, and immune recruitment – offering a multidimensional view of its pharmacology.
https://pubmed.ncbi.nlm.nih.gov/39887892/

2. Metabolomics: Doxorubicin’s Impact in Triple-Negative Breast Cancer
“Metabolic Signatures of Tumor Responses to Doxorubicin Elucidated by Metabolic Profiling in Ovo “
Achkar IW et al. (2020). Metabolites
Combined the CAM assay with untargeted metabolomics and lipidomics to map metabolic shifts following doxorubicin treatment. Results identified suppression of glycolysis and nucleotide synthesis, providing insight into metabolic vulnerabilities induced by therapy.
https://pubmed.ncbi.nlm.nih.gov/32605263/

3. Poster at AACR 2023 – Pharmacological Profiling of Osimertinib
” Pharmacological Mechanisms of Osimertinib in Advanced Non-Small Lung Cancer Bearing the Deletion Exon 19 of EGFR in an Original Chicken ChorioAllantoic Membrane (CAM) Model”
Barthélémy D et al., Inovotion
Presented a detailed MoA analysis of osimertinib in EGFR-mutant tumors using the CAM model, confirming alterations in tumor vascularization, immune modulation, and transcriptomic pathways, aligned with clinical observations.

Download our Poster with HCL at AACR

These studies show that Inovotion’s NAM CAM model goes beyond tumor growth inhibition. It enables high-content MoA studies, providing fast, reproducible, and translatable readouts – critical for optimizing combination strategies, identifying biomarkers, and guiding clinical development.

Next in our series: Metastasis and invasion

Follow us to discover how leading biotech and pharma companies use the CAM model to accelerate and de-risk their oncology pipelines – with robust, reproducible data.
Learn more about our platform: https://www.inovotion.com
Reach out to schedule a meeting with our scientific team or learn more at: https://www.inovotion.com/contact